A Phase Ia/Ib, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Combination With Chemotherapy Followed by Expansion Cohorts in Patients With Advanced Gastrointestinal Cancers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 23 Jan 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Bevacizumab (Primary) ; BI 905711 (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary)
Indications Adenocarcinoma; Colorectal cancer; Gastrointestinal cancer; Pancreatic cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Boehringer Ingelheim

17 Jan 2024 Status changed from discontinued to completed.
07 Dec 2023 Status changed from active, no longer recruiting to discontinued as per company decision.
11 Sep 2023 Planned End Date changed from 16 Sep 2024 to 15 Mar 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com